Effects of the D<inf>1</inf> dopamine receptor agonist dihydrexidine (DAR-0100A) on working memory in schizotypal personality disorder

Daniel R. Rosell, Lauren C. Zaluda, Margaret M. McClure, M. Mercedes Perez-Rodriguez, K. Sloan Strike, Deanna M. Barch, Philip D Harvey, Ragy R. Girgis, Erin A. Hazlett, Richard B. Mailman, Anissa Abi-Dargham, Jeffrey A. Lieberman, Larry J. Siever

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Pharmacological enhancement of prefrontal D<inf>1</inf> dopamine receptor function remains a promising therapeutic approach to ameliorate schizophrenia-spectrum working memory deficits, but has yet to be rigorously evaluated clinically. This proof-of-principle study sought to determine whether the active enantiomer of the selective and full D<inf>1</inf> receptor agonist dihydrexidine (DAR-0100A) could attenuate working memory impairments in unmedicated patients with schizotypal personality disorder (SPD). We performed a randomized, double-blind, placebo-controlled trial of DAR-0100A (15 mg/150 ml of normal saline administered intravenously over 30 min) in medication-free patients with SPD (n=16) who met the criteria for cognitive impairment (ie, scoring below the 25th percentile on tests of working memory). We employed two measures of verbal working memory that are salient to schizophrenia-spectrum cognitive deficits, and that clinical data implicate as being associated with prefrontal D<inf>1</inf> availability: (1) the Paced Auditory Serial Addition Test (PASAT); and (2) the N-back test (ratio of 2-back:0-back scores). Study procedures occurred over four consecutive days, with working memory testing on Days 1 and 4, and DAR-0100A/placebo administration on Days 2-4. Treatment with DAR-0100A was associated with significantly improved PASAT performance relative to placebo, with a very large effect size (Cohen's d=1.14). Performance on the N-back ratio was also significantly improved; however, this effect rested on both a non-significant enhancement and diminution of 2-back and 0-back performance, respectively; therefore interpretation of this finding is more complicated. DAR-0100A was generally well tolerated, with no serious medical or psychiatric adverse events; common side effects were mild to moderate and transient, consisting mainly of sedation, lightheadedness, tachycardia, and hypotension; however, we were able to minimize these effects, without altering the dose, with supportive measures, eg, co-administered normal saline. Although preliminary, these findings lend further clinical support to the potential of D 1 receptor agonists to treat schizophrenia-spectrum working memory impairments. These data suggest a need for further studies with larger group sizes, serum DAR-0100A levels, and a more comprehensive neuropsychological battery.

Original languageEnglish (US)
Pages (from-to)446-453
Number of pages8
JournalNeuropsychopharmacology
Volume40
Issue number2
DOIs
StatePublished - Jan 1 2015

Fingerprint

Schizotypal Personality Disorder
Dopamine Agonists
Short-Term Memory
Schizophrenia
Placebos
Dopamine D1 Receptors
Memory Disorders
Dizziness
dihydrexidine
Tachycardia
Hypotension
Psychiatry
Pharmacology
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health

Cite this

Rosell, D. R., Zaluda, L. C., McClure, M. M., Perez-Rodriguez, M. M., Strike, K. S., Barch, D. M., ... Siever, L. J. (2015). Effects of the D<inf>1</inf> dopamine receptor agonist dihydrexidine (DAR-0100A) on working memory in schizotypal personality disorder. Neuropsychopharmacology, 40(2), 446-453. https://doi.org/10.1038/npp.2014.192

Effects of the D<inf>1</inf> dopamine receptor agonist dihydrexidine (DAR-0100A) on working memory in schizotypal personality disorder. / Rosell, Daniel R.; Zaluda, Lauren C.; McClure, Margaret M.; Perez-Rodriguez, M. Mercedes; Strike, K. Sloan; Barch, Deanna M.; Harvey, Philip D; Girgis, Ragy R.; Hazlett, Erin A.; Mailman, Richard B.; Abi-Dargham, Anissa; Lieberman, Jeffrey A.; Siever, Larry J.

In: Neuropsychopharmacology, Vol. 40, No. 2, 01.01.2015, p. 446-453.

Research output: Contribution to journalArticle

Rosell, DR, Zaluda, LC, McClure, MM, Perez-Rodriguez, MM, Strike, KS, Barch, DM, Harvey, PD, Girgis, RR, Hazlett, EA, Mailman, RB, Abi-Dargham, A, Lieberman, JA & Siever, LJ 2015, 'Effects of the D<inf>1</inf> dopamine receptor agonist dihydrexidine (DAR-0100A) on working memory in schizotypal personality disorder', Neuropsychopharmacology, vol. 40, no. 2, pp. 446-453. https://doi.org/10.1038/npp.2014.192
Rosell, Daniel R. ; Zaluda, Lauren C. ; McClure, Margaret M. ; Perez-Rodriguez, M. Mercedes ; Strike, K. Sloan ; Barch, Deanna M. ; Harvey, Philip D ; Girgis, Ragy R. ; Hazlett, Erin A. ; Mailman, Richard B. ; Abi-Dargham, Anissa ; Lieberman, Jeffrey A. ; Siever, Larry J. / Effects of the D<inf>1</inf> dopamine receptor agonist dihydrexidine (DAR-0100A) on working memory in schizotypal personality disorder. In: Neuropsychopharmacology. 2015 ; Vol. 40, No. 2. pp. 446-453.
@article{9300a3f8e5f34e09a16b43abb7d26883,
title = "Effects of the D1 dopamine receptor agonist dihydrexidine (DAR-0100A) on working memory in schizotypal personality disorder",
abstract = "Pharmacological enhancement of prefrontal D1 dopamine receptor function remains a promising therapeutic approach to ameliorate schizophrenia-spectrum working memory deficits, but has yet to be rigorously evaluated clinically. This proof-of-principle study sought to determine whether the active enantiomer of the selective and full D1 receptor agonist dihydrexidine (DAR-0100A) could attenuate working memory impairments in unmedicated patients with schizotypal personality disorder (SPD). We performed a randomized, double-blind, placebo-controlled trial of DAR-0100A (15 mg/150 ml of normal saline administered intravenously over 30 min) in medication-free patients with SPD (n=16) who met the criteria for cognitive impairment (ie, scoring below the 25th percentile on tests of working memory). We employed two measures of verbal working memory that are salient to schizophrenia-spectrum cognitive deficits, and that clinical data implicate as being associated with prefrontal D1 availability: (1) the Paced Auditory Serial Addition Test (PASAT); and (2) the N-back test (ratio of 2-back:0-back scores). Study procedures occurred over four consecutive days, with working memory testing on Days 1 and 4, and DAR-0100A/placebo administration on Days 2-4. Treatment with DAR-0100A was associated with significantly improved PASAT performance relative to placebo, with a very large effect size (Cohen's d=1.14). Performance on the N-back ratio was also significantly improved; however, this effect rested on both a non-significant enhancement and diminution of 2-back and 0-back performance, respectively; therefore interpretation of this finding is more complicated. DAR-0100A was generally well tolerated, with no serious medical or psychiatric adverse events; common side effects were mild to moderate and transient, consisting mainly of sedation, lightheadedness, tachycardia, and hypotension; however, we were able to minimize these effects, without altering the dose, with supportive measures, eg, co-administered normal saline. Although preliminary, these findings lend further clinical support to the potential of D 1 receptor agonists to treat schizophrenia-spectrum working memory impairments. These data suggest a need for further studies with larger group sizes, serum DAR-0100A levels, and a more comprehensive neuropsychological battery.",
author = "Rosell, {Daniel R.} and Zaluda, {Lauren C.} and McClure, {Margaret M.} and Perez-Rodriguez, {M. Mercedes} and Strike, {K. Sloan} and Barch, {Deanna M.} and Harvey, {Philip D} and Girgis, {Ragy R.} and Hazlett, {Erin A.} and Mailman, {Richard B.} and Anissa Abi-Dargham and Lieberman, {Jeffrey A.} and Siever, {Larry J.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1038/npp.2014.192",
language = "English (US)",
volume = "40",
pages = "446--453",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Effects of the D1 dopamine receptor agonist dihydrexidine (DAR-0100A) on working memory in schizotypal personality disorder

AU - Rosell, Daniel R.

AU - Zaluda, Lauren C.

AU - McClure, Margaret M.

AU - Perez-Rodriguez, M. Mercedes

AU - Strike, K. Sloan

AU - Barch, Deanna M.

AU - Harvey, Philip D

AU - Girgis, Ragy R.

AU - Hazlett, Erin A.

AU - Mailman, Richard B.

AU - Abi-Dargham, Anissa

AU - Lieberman, Jeffrey A.

AU - Siever, Larry J.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Pharmacological enhancement of prefrontal D1 dopamine receptor function remains a promising therapeutic approach to ameliorate schizophrenia-spectrum working memory deficits, but has yet to be rigorously evaluated clinically. This proof-of-principle study sought to determine whether the active enantiomer of the selective and full D1 receptor agonist dihydrexidine (DAR-0100A) could attenuate working memory impairments in unmedicated patients with schizotypal personality disorder (SPD). We performed a randomized, double-blind, placebo-controlled trial of DAR-0100A (15 mg/150 ml of normal saline administered intravenously over 30 min) in medication-free patients with SPD (n=16) who met the criteria for cognitive impairment (ie, scoring below the 25th percentile on tests of working memory). We employed two measures of verbal working memory that are salient to schizophrenia-spectrum cognitive deficits, and that clinical data implicate as being associated with prefrontal D1 availability: (1) the Paced Auditory Serial Addition Test (PASAT); and (2) the N-back test (ratio of 2-back:0-back scores). Study procedures occurred over four consecutive days, with working memory testing on Days 1 and 4, and DAR-0100A/placebo administration on Days 2-4. Treatment with DAR-0100A was associated with significantly improved PASAT performance relative to placebo, with a very large effect size (Cohen's d=1.14). Performance on the N-back ratio was also significantly improved; however, this effect rested on both a non-significant enhancement and diminution of 2-back and 0-back performance, respectively; therefore interpretation of this finding is more complicated. DAR-0100A was generally well tolerated, with no serious medical or psychiatric adverse events; common side effects were mild to moderate and transient, consisting mainly of sedation, lightheadedness, tachycardia, and hypotension; however, we were able to minimize these effects, without altering the dose, with supportive measures, eg, co-administered normal saline. Although preliminary, these findings lend further clinical support to the potential of D 1 receptor agonists to treat schizophrenia-spectrum working memory impairments. These data suggest a need for further studies with larger group sizes, serum DAR-0100A levels, and a more comprehensive neuropsychological battery.

AB - Pharmacological enhancement of prefrontal D1 dopamine receptor function remains a promising therapeutic approach to ameliorate schizophrenia-spectrum working memory deficits, but has yet to be rigorously evaluated clinically. This proof-of-principle study sought to determine whether the active enantiomer of the selective and full D1 receptor agonist dihydrexidine (DAR-0100A) could attenuate working memory impairments in unmedicated patients with schizotypal personality disorder (SPD). We performed a randomized, double-blind, placebo-controlled trial of DAR-0100A (15 mg/150 ml of normal saline administered intravenously over 30 min) in medication-free patients with SPD (n=16) who met the criteria for cognitive impairment (ie, scoring below the 25th percentile on tests of working memory). We employed two measures of verbal working memory that are salient to schizophrenia-spectrum cognitive deficits, and that clinical data implicate as being associated with prefrontal D1 availability: (1) the Paced Auditory Serial Addition Test (PASAT); and (2) the N-back test (ratio of 2-back:0-back scores). Study procedures occurred over four consecutive days, with working memory testing on Days 1 and 4, and DAR-0100A/placebo administration on Days 2-4. Treatment with DAR-0100A was associated with significantly improved PASAT performance relative to placebo, with a very large effect size (Cohen's d=1.14). Performance on the N-back ratio was also significantly improved; however, this effect rested on both a non-significant enhancement and diminution of 2-back and 0-back performance, respectively; therefore interpretation of this finding is more complicated. DAR-0100A was generally well tolerated, with no serious medical or psychiatric adverse events; common side effects were mild to moderate and transient, consisting mainly of sedation, lightheadedness, tachycardia, and hypotension; however, we were able to minimize these effects, without altering the dose, with supportive measures, eg, co-administered normal saline. Although preliminary, these findings lend further clinical support to the potential of D 1 receptor agonists to treat schizophrenia-spectrum working memory impairments. These data suggest a need for further studies with larger group sizes, serum DAR-0100A levels, and a more comprehensive neuropsychological battery.

UR - http://www.scopus.com/inward/record.url?scp=84926393206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926393206&partnerID=8YFLogxK

U2 - 10.1038/npp.2014.192

DO - 10.1038/npp.2014.192

M3 - Article

C2 - 25074637

AN - SCOPUS:84926393206

VL - 40

SP - 446

EP - 453

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 2

ER -